Valbiotis SAS (France) Today
| ALVAL Stock | EUR 1.37 0.02 1.48% |
Performance2 of 100
| Odds Of DistressLess than 31
|
Valbiotis SAS is selling at 1.37 as of the 24th of December 2024; that is 1.48 percent up since the beginning of the trading day. The stock's last reported lowest price was 1.34. Valbiotis SAS has about a 31 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 24th of November 2024 and ending today, the 24th of December 2024. Click here to learn more.
Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. Valbiotis SA was founded in 2014 and is based in Prigny, France. VALBIOTIS is traded on Paris Stock Exchange in France. The company has 12.41 M outstanding shares. More on Valbiotis SAS
Moving against Valbiotis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Valbiotis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Valbiotis SAS's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Valbiotis SAS or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Valbiotis SAS (ALVAL) is traded on Euronext Paris in France and employs 5,000 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 50.38 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Valbiotis SAS's market, we take the total number of its shares issued and multiply it by Valbiotis SAS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Valbiotis SAS operates under Biotechnology sector and is part of Health Care industry. The entity has 12.41 M outstanding shares.
Valbiotis SAS has accumulated about 541 K in cash with (7.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Valbiotis SAS Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Valbiotis SAS is €50.38 Million. Valbiotis SAS has 8.39 % of its outstanding shares held by insiders and 7.32 % owned by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Valbiotis Ownership Details
Valbiotis SAS Risk Profiles
Although Valbiotis SAS's alpha and beta are two of the key measurements used to evaluate Valbiotis SAS's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.52 | |||
| Semi Deviation | 2.19 | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.93 |
Valbiotis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Valbiotis SAS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Valbiotis SAS Corporate Management
Elected by the shareholders, the Valbiotis SAS's board of directors comprises two types of representatives: Valbiotis SAS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valbiotis. The board's role is to monitor Valbiotis SAS's management team and ensure that shareholders' interests are well served. Valbiotis SAS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valbiotis SAS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sbastien HDR | Chairman CoFounder | Profile | |
| Sebastien Bessy | COO Board | Profile | |
| Pascal Sirvent | CSO Board | Profile | |
| Fedrick Pelong | CFO Director | Profile | |
| Philippe Sibour | Chief Consulting | Profile | |
| Murielle Cazaubiel | CMO Board | Profile | |
| Josep Infesta | Head Devel | Profile |
Additional Tools for Valbiotis Stock Analysis
When running Valbiotis SAS's price analysis, check to measure Valbiotis SAS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valbiotis SAS is operating at the current time. Most of Valbiotis SAS's value examination focuses on studying past and present price action to predict the probability of Valbiotis SAS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valbiotis SAS's price. Additionally, you may evaluate how the addition of Valbiotis SAS to your portfolios can decrease your overall portfolio volatility.